

INTRODUCTION

- Currently, the incidence of diabetes in children is increasing and may coexist with growth hormone deficiency (GHD)¹.
- In diabetic patients, there are many mechanisms which disrupt the growth process and affect the GH/IGF-1 axis ². However, with properly controlled diabetes, patients achieve normal height and should be diagnosed for causes of short stature other than diabetes ³.
- There are few reports on the safety and effects of the use of recombinant human growth hormone (rhGH) in patients with GHD and type 1 diabetes ^{4,5,6}.

AIM

rhGH Demonstration of the effects of treatment in a patient with GHD and type 1 diabetes.

CASE STUDY

- The girl was diagnosed with diabetes at the age of 15 months and treated with continuous subcutaneous insulin infusion with good compensation.
- From the age of 2, the child's growth curve was below the 3rd percentile.
- Family history revealed that the child's father had been treated with rhGH for GHD.
- 6 years bone age 4.5 years
- Karyotype 46 XX


Test	0'	30'	60'	90 '	120'
nocturnal GH peak (ng/ml)	0,53	4,65	1,27	4,05	2,2
GH after clonidine (ng/ml)	0,45	1,77	9,38	6,91	3,48


• At the age of 7 and 2 months, the girl started rhGH therapy.

A. RAKUS-KWIATOSZ¹, B. BANECKA² and I. BEN-SKOWRONEK³ 1. Department of Propaedeutics of Paediatrics, Medical University of Lublin, Poland 2. Department of Paediatric Endocrinology and Diabetology, Medical University of Lublin, Poland

THE RESULTS OF TREATMENT WITH GROWTH HORMONE IN A PATIENT WITH GROWTH HORMONE DEFICIENCY AND TYPE 1 DIABETES

RESULTS





Start of r administr

0.6 U/kg/

CONCLUSIONS

- In diabetic patients, it is advisable to also look for reasons of short stature other than metabolic imbalance, because children with well-controlled diabetes are not affected by growth disorders.
- Based on the literature and our own observations, it seems that treating diabetic children with rhGH is **safe** and **beneficial**.
- There is a need to conduct research on larger groups to assess the **safety** and effects of rhGH therapy in children with type 1 diabetes.

CONTACT INFORMATION

Anna Rakus-Kwiatosz (e-mail: annarakuskwiatosz@umlub.pl)

IGF-1 concentration

Insulin requirements


	After one year of treatment	Currently
/day	1.0 U/kg/day	0.9 U/kg/day

REFERENCES

[%]

- 2017:34:13-21.
- Pediatr 2018;198:260-4.
- *(Oxf).* 2003;58(3):309-15.





Glycated hemoglobin concentration

There were no signs of diabetic retinopathy.

1. Bonfig W., Molz K., Woelfle J. et al. Metabolic Safety of Growth Hormone in Type 1 Diabetes and Idiopathic Growth Hormone Deficiency. J Pediatr 2013;163:1095-98.

2. Giannini, C., Mohn, A., & Chiarelli, F. Growth Abnormalities in Children with Type 1 Diabetes, Juvenile Chronic Arthritis, and Asthma. Int J Endocrinol, 2014, 265954.

3. Raisingani M., Preneet B., Kohn B., & Yakar S. Skeletal growth and bone mineral acquisition in type 1 diabetic children; abnormalities of the GH/IGF-1 axis. Growth Horm IGF Res.

4. Bonfig W., Lindberg A., Carlsson M. et al. Efficacy of Growth Hormone Treatment in Children with Type 1 Diabetes Mellitus and Growth Hormone Deficiency—An Analysis of KIGS Data. J

5. Christ E.R., Simpson H.L., Breen L. et al. The effect of growth hormone (GH) replacement therapy in adult patients with type 1 diabetes mellitus and GH deficiency. *Clin Endocrinol*

6. Zucchini S., Iafusco D., Vanelli S. et al. Combined therapy with insulin and growth hormone in 17 patients with type-1 diabetes and growth disorders. Horm Res Pediatr. 2014;82(1):53-8.

I pi GH ar Anna

P2-273

29ESPE

pocter. Bossion